Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Xilis is raising $4,849,998.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Xiling Shen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Xilis

Xilis is developing next generation organoid technologies to guide precision therapy for cancer patients and accelerate drug discovery. Cancer is the second leading cause of death in the U.S and metastatic disease remains predominantly incurable. New cancer cases and healthcare costs continue to increase year-over-year. Precision medicine helps select the most effective treatments for patients.

To learn more about Xilis, visit http://www.xilis.net/

Contact:
Xiling Shen, Chief Executive Officer
607-397-4121

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved